NextPlat (NXPL) Cash & Current Investments (2014 - 2026)
NextPlat's (NXPL) quarterly Cash & Current Investments came in at $11.9 million in Q2 2026, down 28.22% year-over-year from $16.6 million in Q2 2025, and up 8.47% quarter-over-quarter from $11.0 million in Q1 2026.
Analysis
NextPlat (NXPL) Cash & Current Investments (2014 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Cash & Current Investments for 13 consecutive years, with $11.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash & Current Investments fell 28.22% year-over-year to $11.9 million in Q2 2026; TTM through Jun 2026 was $11.9 million, a 28.22% decrease from a year earlier, with the FY2025 full-year figure at $13.7 million, down 31.32% from the prior year.
- Cash & Current Investments was $11.9 million for Q2 2026 at NextPlat, up from $11.0 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $26.3 million in Q3 2023 and troughed at $11.0 million in Q1 2026.
- A 5-year average of $18.7 million and a median of $19.4 million in 2022 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments jumped 3817.15% in 2022 and tumbled 37.94% in 2026, its largest moves.
- Over 5 years, Cash & Current Investments stood at $18.9 million in 2022, then surged by 39.26% to $26.3 million in 2023, then fell by 24.13% to $20.0 million in 2024, then sank by 31.32% to $13.7 million in 2025, then decreased by 12.9% to $11.9 million in 2026.
- The last three Cash & Current Investments figures came in at $11.9 million (Q2 2026), $11.0 million (Q1 2026), and $13.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 3.66 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 886.50 Mn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 171.67 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 127.64 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 1.84 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 360.25 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 142.75 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 290.12 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 41.25 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 11.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.94 Mn |
| Mar 31, 2026 | 11.01 Mn |
| Dec 31, 2025 | 13.71 Mn |
| Sep 30, 2025 | 13.93 Mn |
| Jun 30, 2025 | 16.64 Mn |
| Mar 31, 2025 | 17.74 Mn |
| Dec 31, 2024 | 19.96 Mn |
| Sep 30, 2024 | 20.36 Mn |
| Jun 30, 2024 | 24.88 Mn |
| Mar 31, 2024 | 23.53 Mn |
| Dec 31, 2023 | 26.31 Mn |
| Sep 30, 2023 | 26.35 Mn |
| Jun 30, 2023 | 20.61 Mn |
| Mar 31, 2023 | 16.72 Mn |
| Dec 31, 2022 | 18.89 Mn |
| Sep 30, 2022 | 12.47 Mn |
| Jun 30, 2022 | 20.47 Mn |
| Mar 31, 2022 | 21.91 Mn |
| Dec 31, 2021 | 17.27 Mn |
| Sep 30, 2021 | 17.14 Mn |